Drugs / LG002
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06329908 | Sep 2023 → Sep 2024 overdue | lung cancer | Zhen-Yu Ding | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00366041 | Feb 2006 → Dec 2008 | — | Laboratoires Genévrier | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LG002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00366041 ↗ |
| Modality | Vaccine | “Neoantigen-loaded Dendritic Cell Vaccine (Neo-DCVac)” NCT06329908 ↗ |
| Route | Subcutaneous | “subcutaneous multi-point injection” NCT06329908 ↗ |